Performance criteria for combined uncertainty budget in the implementation of metrological traceability

被引:68
作者
Braga, Federica [1 ]
Infusino, Ilenia [1 ]
Panteghini, Mauro [1 ]
机构
[1] Univ Milan, Ctr Metrol Traceabil Lab Med CIRME, Milan, Italy
关键词
analytical goals; standardization; uncertainty; STANDARDIZATION; QUALITY; SPECIFICATIONS; CREATININE; GOALS;
D O I
10.1515/cclm-2014-1240
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The measurement uncertainty budget should combine the uncertainty of higher order references, the uncertainty of commercial system calibration, the system imprecision and individual laboratory performance in terms of variability. Here we recommend that no more than one third of the total uncertainty budget, established by appropriate analytical performance specifications, is consumed by the uncertainty of references and approximately 50% of the total budget consumed by the manufacturer's calibration and value transfer protocol. The remaining 50% should be available for the commercial system imprecision (including the batch to batch variation of the reagents) and individual laboratory performance in order to fulfil the uncertainty goal. For commercial systems to work properly, in vitro diagnostics (IVD) manufacturers will need to take more responsibility and ensure the traceability of the combination of platform, reagents, calibrators and control materials for system alignment verification that only as such (as a whole) are certified ("CE marked") by the manufacturer itself in terms of traceability to the selected reference measurement system. Particularly, IVD manufacturers should report the combined (expanded) uncertainty associated with their calibrators when used in conjunction with other components of their analytical system (platform and reagents). This is more than what they are currently providing as traceability and uncertainty information.
引用
收藏
页码:905 / 912
页数:8
相关论文
共 28 条
[1]  
[Anonymous], 2007, CERT AN STAND REF MA
[2]  
[Anonymous], 2009, ISO 15194:2009 Invitro diagnostic medical devices measurement of quantities in samples of biological origin requirements for certified reference materials and the content of supporting documentation
[3]  
[Anonymous], 1998, OFF J EUR UNION L, VL331, P1
[4]  
[Anonymous], 2003, ISO
[5]  
[Anonymous], 5 INT SCI M STAND CA
[6]   Defining acceptable limits for the metrological traceability of specific measurands [J].
Bais, Renze ;
Armbruster, Dave ;
Jansen, Rob T. P. ;
Klee, George ;
Panteghini, Mauro ;
Passarelli, Joseph ;
Sikaris, Ken A. .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (05) :973-979
[7]   Gaps in the Traceability Chain of Human Growth Hormone Measurements [J].
Boulo, Sebastien ;
Hanisch, Katja ;
Bidlingmaier, Martin ;
Arsene, Cristian-Gabriel ;
Panteghini, Mauro ;
Auclair, Guy ;
Sturgeon, Catharine ;
Schimmel, Heinz ;
Zegers, Ingrid .
CLINICAL CHEMISTRY, 2013, 59 (07) :1074-1082
[8]   Verification of in vitro medical diagnostics (IVD) metrological traceability: Responsibilities and strategies [J].
Braga, Federica ;
Panteghini, Mauro .
CLINICA CHIMICA ACTA, 2014, 432 :55-61
[9]   Standardization and analytical goals for glycated hemoglobin measurement [J].
Braga, Federica ;
Panteghini, Mauro .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (09) :1719-1726
[10]   Estimate of intraindividual variability of C-reactive protein: A challenging issue [J].
Braga, Federica ;
Ferraro, Simona ;
Szoke, Dominika ;
Panteghini, Mauro .
CLINICA CHIMICA ACTA, 2013, 419 :85-86